Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Illumina Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.illumina.com
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Jacob Thaysen, PhD
Number Of Employees: 10,370
Enterprise Value: $22,649,171,590
PE Ratio: -10.66
Exchange/Ticker 1: NASDAQ:ILMN
Exchange/Ticker 2: N/A
Latest Market Cap: $13,033,152,512
BioCentury | Mar 26, 2025
Management Tracks
FDA names Barclay Butler COO
Plus: Scott Gottlieb named chair of Illumina, and updates from Syncromune and OSR
BioCentury | Jan 16, 2025
Politics, Policy & Law
FDA veterans school Makary
Califf, Gottlieb, McClellan, Woodcock advise the next commissioner to collaborate with staff, push change to keep up with scientific advances
BioCentury | Dec 5, 2024
Politics, Policy & Law
Biosecure compromise in the works, fate uncertain as deadline nears
Deal among lawmakers would give targeted companies chance to avoid sanctions
BioCentury | Nov 19, 2024
Politics, Policy & Law
As Congress considers Biosecure, report says WuXi companies low-risk
Rhodium Group report suggests Congress focus on economic rather than military threats from China biotech
BioCentury | Oct 24, 2024
Politics, Policy & Law
FDA must be protected from politics, say Califf, ex-agency leaders
Celebrating Richard Pazdur’s 25th anniversary, former FDA commissioners say political pressures have intensified
BioCentury | Oct 4, 2024
Management Tracks
Resolution names Paul Sekhri chair
Plus: Dadswell leaving Illumina as general counsel and updates from Eliem, Codexis, Oculis, Illumina, Eupraxia and PharmaJet
BioCentury | Sep 19, 2024
Discovery & Translation
Science Spotlight: Cancer prognosis via deep learning, new protein degraders, and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | Sep 4, 2024
Politics, Policy & Law
Illumina’s Pyrrhic victory in European case over Grail acquisition
Illumina share price has fallen 55% since Grail deal announced
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
Items per page:
1 - 10 of 735